AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29454514
Drug: Continuous linsitinib
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous linsitinib (150mg twice daily) with paclitaxel (80mg/m2 on Days 1, 8, and 15)
Trial: 26857248
Drug: Balneotherapy (BT)
RxNorm normalized name: BTS
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (BT) in addition to physical therapy (PT)
Trial: 24172160
Drug: Levomilnacipran ER
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran ER 75 or 100 mg/day
Trial: 17311014
Drug: Pharmacy technician‐led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacy technician‐led medication review and counselling clinic
Trial: 11593218
Drug: 3-minute adenosine
RxNorm normalized name: adenosine 3 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-minute adenosine infusion at 140 microg/kg per minute
Trial: 11593218
Drug: 6-minute adenosine
RxNorm normalized name: adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-minute adenosine infusion at 140 microg/kg per minute
Trial: 9638504
Drug: Lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine clonixinate (125 mg tablet every 4 h for 2 days)
Trial: 9638504
Drug: Paracetamol/codeine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/codeine (500 mg + 30 mg every 4 h for 2 days)
Trial: 9638504
Drug: Paracetamol/codeine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol/codeine (500 mg + 30 mg)
Trial: 9638504
Drug: Lysine clonixinate
RxNorm normalized name: lysine clonixinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine clonixinate (125 mg)
Trial: 1138844
Drug: Intravenous Diamox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Diamox with variable doses of Pilocarpine
Trial: 27299461
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of Shenmai Injection (0.6 mL/kg in 10 mL normal saline)
Trial: 27299461
Drug: Intravenous drip
RxNorm normalized name: DRIP COLLECTOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drip of Shenmai Injection (0.6 mL/kg dissolved in 250 mL of 10% glucose)
Trial: 17160910
Drug: DPP IV
RxNorm normalized name: L-DPPG-Na
DrugBank: Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DB14105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP IV inhibitors (gliptins)
Trial: 12532097
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily
Trial: 12532097
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 microg administered twice daily
Trial: 11233712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelastine and beclomethasone administered together (morning and evening, with a 5-minute interval)
Trial: 11233712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelastine and beclomethasone administered separately (azelastine in the morning and evening, beclomethasone later during the morning and in the afternoon)
Trial: 11233712
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelastine and beclomethasone
Trial: 8895908
Drug: 89Sr (148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Sr (148 MBq) followed by carboplatin (100 mg m‐2 at 7 and 21 days)
Trial: 1900379
Drug: deferoxamine (chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deferoxamine (chelation therapy)
Trial: 1900379
Drug: no chelation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no chelation therapy (control group)
Trial: 31764095
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral tenofovir disoproxil fumarate (TDF) for preexposure prophylaxis (PrEP)
Trial: 24747867
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day (n=86)
Trial: 24747867
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 135 μg/week (n=86)
Trial: 24473718
Drug: Low-fluoride dentifrices
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluoride dentifrices (0-275, 275-550, 550-1,100 µg F/g)
Trial: 24473718
Drug: Low-fluoride dentifrices
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluoride dentifrices (1,100 µg F/g)
Trial: 10934930
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and midazolam coinduction
Trial: 9058494
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid administered intravenously at the end of the operation, repeated three hours later.
Trial: 9058494
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered to control group.
Trial: 27055643
Drug: Saline (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (0.1 ml/kg)
Trial: 21934521
Drug: Lipo‐PGE1 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipo‐PGE1 (20 μg/day intravenously for 5 days)
Trial: 16941968
Drug: Comprehensive program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive program of physical therapy
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) 0.1 mg
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) 0.2 mg
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) 0.3 mg
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) 0.0 mg (control)
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) (0.1, 0.2, 0.3 mg)
Trial: 14570664
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (ITMS) (0.2 mg)
Trial: 10761163
Drug: Acetaminophen controlled-release
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen controlled-release (CR) sprinkles on applesauce
Trial: 10761163
Drug: Acetaminophen immediate-release
RxNorm normalized name: acetaminophen Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen immediate-release (IR) elixir
Trial: 8881732
Drug: Chemotherapy (epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (epirubicin, cisplatin, and 5‐fluorouracil)
Trial: 1553892
Drug: Bepridil hydrochloride
RxNorm normalized name: Bepridil Hydrochloride
DrugBank: Bepridil (DB01244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepridil hydrochloride (HCl) at a mean maintenance dosage of 324 mg/day
Trial: 3296615
Drug: DDS 100
RxNorm normalized name: DDS
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DDS 100 mg 7/7 for 3 years
Trial: 3296615
Drug: RMP 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP 900 mg 1/7 for 8 doses
Trial: 3296615
Drug: RMP 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMP 900 mg 7/7 for 12 doses
Trial: 29551889
Drug: β‐asarone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β‐asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5‐20 mg/d
Trial: 29551889
Drug: memantine 5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: memantine 5‐20 mg/d
Trial: 15704687
Drug: Qianlie Sanyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qianlie Sanyu Capsule
Trial: 8077472
Drug: Topical propylthiouracil
RxNorm normalized name: Propylthiouracil
DrugBank: Propylthiouracil (DB00550)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical propylthiouracil (PTU), applied three times daily for 4 to 8 weeks
Trial: 1087743
Drug: Ketoprofen (KETO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (KETO), 200 mg daily
Trial: 1087743
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA), 3.6 g daily
Trial: 26652797
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of quadrivalent HPV vaccine on days 1, 60, and 180 or later
Trial: 26652797
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of quadrivalent HPV vaccine on days 1 and 180 or later
Trial: 26652797
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of quadrivalent HPV vaccine on days 1 and 60 by default
Trial: 26652797
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of quadrivalent HPV vaccine by default
Trial: 24613188
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg sildenafil citrate
Trial: 20633189
Drug: Active eradication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active eradication therapy
Trial: 12442020
Drug: 9-valent pneumococcal
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-valent pneumococcal conjugate vaccine (n = 250)
Trial: 10373132
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 1 mg twice daily for three nights and 500 microg twice daily for 11 nights
Trial: 21624883
Drug: HibMenCY vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HibMenCY vaccine
Trial: 21624883
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccine (ActHIB) and PedvaxHIB
Trial: 16454149
Drug: Specific acupressure
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific acupressure treatment
Trial: 16454149
Drug: Placebo acupressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo acupressure treatment
Trial: 11731064
Drug: 1.0mg morphine-HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg morphine-HCl
Trial: 11731064
Drug: 0.1mg morphine-HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mg morphine-HCl
Trial: 9041945
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rHuGH) for 1 year
Trial: 8185094
Drug: Nasal cannula
RxNorm normalized name: EUCALYPTUS OIL 0.15 g in 1 g / MENTHOL, UNSPECIFIED FORM 0.2 g in 1 g / ARGININE 0.1 g in 1 g TOPICAL CREAM [Slimming Detox Nasal Cannula]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal cannula (at 10 L/min)
Trial: 8185094
Drug: Oxygen supply
RxNorm normalized name: Oxygen Supply Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen supply tubing (at 15 L/min)
Trial: 23834410
Drug: Propofol-remifentanil (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol-remifentanil (group PR) - 56 μg/kg/min of propofol and 0.06 μg/kg/min of remifentanil
Trial: 18492366
Drug: Short GnRH
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short GnRH agonist protocol with buserelin nasal sprays from day 2 and recombinant FSH from day 5
Trial: 18492366
Drug: Long GnRH
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long GnRH agonist protocol with buserelin from previous mid-luteal phase and recombinant FSH after down-regulation
Trial: 8919897
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of nitric oxide (NO) at a concentration of 30 ppm
Trial: 1882901
Drug: Sucralfate suspension
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucralfate suspension (1 g q.i.d. for a maximum of 3 weeks)
Trial: 7051805
Drug: CFP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFP with radiation therapy
Trial: 29140831
Drug: HBOC-201 (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC-201 (13 g Hb/dL)
Trial: 29140831
Drug: Packed red
RxNorm normalized name: Packed red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packed red blood cells (pRBCs) (24 g Hb/dL)
Trial: 29140831
Drug: PolyHeme (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PolyHeme (10 g Hb/dL)
Trial: 15134988
Drug: Apomorphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine 2 mg
Trial: 11915639
Drug: Topical analgesics
RxNorm normalized name: ANALGESIC TOP GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesics or systemic pain medications
Trial: 9517578
Drug: Salbutamol combined
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol combined with flunisolide (1 mg every 10 min for 3 hours)
Trial: 31465093
Drug: Fulvestrant plus
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant plus daily vistusertib
Trial: 24267513
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - single dose of 2 grams
Trial: 21282444
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of solithromycin (50 to 1,600 mg)
Trial: 21282444
Drug: Seven oral
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven oral daily doses of solithromycin (200 to 600 mg)
Trial: 21282444
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of solithromycin (400 mg) with food
Trial: 21282444
Drug: All dose
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All dose regimens of solithromycin
Trial: 19815268
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate 20 mg per day (n=243)
Trial: 17187417
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily for 3 months
Trial: 9779681
Drug: Rebox stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebox stimulation applied daily for 3 days using a negatively charged probe electrode, at pulse duration of 100 microsec, amplitude of 160 microamp, and frequency of 3000 Hz.
Trial: 7827943
Drug: 10.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10.5 g wheat fibre (Trifyba) daily for 12 weeks
Trial: 7827943
Drug: 60 ml
RxNorm normalized name: Disposable Nurser 60 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 ml lactulose daily for 12 weeks
Trial: 3335948
Drug: Intermittent regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent regimen (60 mg/m2/day for 4 weeks, followed by 40 mg/m2/day on 3 days a week for 4 weeks)
Trial: 3335948
Drug: Long-term tapering
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term tapering regimen (60 mg/m2/day for 4 weeks, followed by the same dose on alternate days for 4 weeks and tapering by 10 mg/m2 on alternate days every 4 weeks for 5 months)
Trial: 26077412
Drug: Etanercept (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (50 mg/week) or Adalimumab (40 mg/2 week) subcutaneously for 1 year
Trial: 21605608
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 6 mg kg⁻¹ BM
Trial: 19598210
Drug: Heavy alcohol
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy alcohol consumption (>=50 g of alcohol daily)
Trial: 19598210
Drug: Regular heavy
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular heavy drinking (>=4 drinks daily on >=5 days per week)
Trial: 19598210
Drug: Drinking >=50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking >=50 g of alcohol daily in the finasteride arm
Trial: 16452559
Drug: Risperidone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (3 mg daily for 8 weeks)
Trial: 8652810
Drug: Intensive timing
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 10 days after first cycle)
Trial: 8652810
Drug: Standard timing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timing induction therapy (4-day cycle of five active chemotherapeutic agents, second cycle 14 days or later after first cycle)
Trial: 6202993
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy (twice a week for 24 weeks)
Trial: 30487976
Drug: MOVEdiabetes intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MOVEdiabetes intervention (personalized consultations by dietitians, pedometers, monthly WhatsApp messages)
Trial: 28534446
Drug: Experimental-High (EXP-High)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental-High (EXP-High) diet with 1000 mg n-3 fatty acids per serving
Trial: 23899653
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic supplement
Trial: 10426331
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide tablets (800 to 1,200 mg/day)
Trial: 7500451
Drug: Continuous bladder
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bladder irrigation with 50 mg/l amphotericin B infused during 24 hours for 2 days
Trial: 7500451
Drug: Intermittent bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bladder irrigations of 10 mg/100 ml amphotericin B in 1 day
Trial: 2104135
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (A/Cl) for 10 days
Trial: 2104135
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (A/Cl) for 3 days
Trial: 2104135
Drug: Trimethoprim (TMP)
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim (TMP) as a single dose
Trial: 6105556
Drug: No surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No surgery (medical treatment)
Trial: 31836291
Drug: Intraperitoneal lavage
RxNorm normalized name: lovage oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal lavage with 50 mL of 0.2% bupivacaine
Trial: 28353221
Drug: PEG-IFN-containing treatment
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN-containing treatment
Trial: 25886874
Drug: etoricoxib 10/30/60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib 10/30/60 mg
Trial: 23536466
Drug: L-protocol (lengthening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-protocol (lengthening exercises)
Trial: 19185400
Drug: Calcium (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1,200 mg) and vitamin D(3) (800 IU) supplementation
Trial: 15355651
Drug: Brachy-chemotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachy-chemotherapy group (n = 18)
Trial: 11493740
Drug: Low-molecular-weight HES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight HES preparation (6% HES, MW 70,000)